Patent Holder
Towia Libermann
Libermann TA, Oettgen JP, Kunsch CA, inventors; Human Genome Sciences, Inc. assignee. NERF genes. US patent 5,721,113. 1995 Jan 3.
Strom T, Libermann TA, inventors; Beth Israel Hospital Association, assignee. Methods and compounds for prevention of graft rejection. US patent 5,958,403. 1999 Sept. 28.
Oettgen JP, Libermann TA, Goldring M, inventors; Beth Israel Deaconess Medical Center, assignee, Use of transcription factors for treating inflammation and other diseases. US patent 6,869,929. 2005, March 22
Oettgen JP, Libermann TA, inventors; Beth Israel Deaconess Medical Center, assignee, Novel transcriptional mediators of blood vessel development and endothelial differentiation. US patent 6,960,444. 2005, November 1
Libermann TA, Oettgen JP, Kunsch CA, Endress GA, Rosen CA, inventors; Human Genome Sciences, Inc. assignee. Prostate derived Ets factor. US patent application 20010010934. 2001 Aug 2.
Strom T, Libermann TA, inventors; Beth Israel Hospital Association, assignee. Methods and compounds for prevention of graft rejection. US patent 20030223970. 2001, March 12.
Oettgen JP, Rigby A, Libermann TA, inventors; Beth Israel Deaconess Medical Center, assignee, Identification and use of small molecules to modulate ESE-1 transcription factor function and to treat ESE-1 transcription factor associated diseases. US patent 2007/023431. 2007, June 11.
Oettgen JP, Rigby A, Libermann TA, inventors; Beth Israel Deaconess Medical Center, assignee, Identification and use of small molecules to modulate transcription factor function and to treat transcription factor associated diseases. US patent 2007/023429. 2007, June 11.
Oettgen JP, Rigby A, Libermann TA, inventors; Beth Israel Deaconess Medical Center, assignee, Identification and use of small molecules to modulate PDEF transcription factor function and to treat PDEF transcription factor associated diseases. US patent 2007/023430. 2007, June 11.
Strom T, Libermann TA, inventors; Beth Israel Hospital Association, assignee. Methods and compounds for prevention of graft rejection. US patent 5,958,403. 1999 Sept. 28.
Oettgen JP, Libermann TA, Goldring M, inventors; Beth Israel Deaconess Medical Center, assignee, Use of transcription factors for treating inflammation and other diseases. US patent 6,869,929. 2005, March 22
Oettgen JP, Libermann TA, inventors; Beth Israel Deaconess Medical Center, assignee, Novel transcriptional mediators of blood vessel development and endothelial differentiation. US patent 6,960,444. 2005, November 1
Libermann TA, Oettgen JP, Kunsch CA, Endress GA, Rosen CA, inventors; Human Genome Sciences, Inc. assignee. Prostate derived Ets factor. US patent application 20010010934. 2001 Aug 2.
Strom T, Libermann TA, inventors; Beth Israel Hospital Association, assignee. Methods and compounds for prevention of graft rejection. US patent 20030223970. 2001, March 12.
Oettgen JP, Rigby A, Libermann TA, inventors; Beth Israel Deaconess Medical Center, assignee, Identification and use of small molecules to modulate ESE-1 transcription factor function and to treat ESE-1 transcription factor associated diseases. US patent 2007/023431. 2007, June 11.
Oettgen JP, Rigby A, Libermann TA, inventors; Beth Israel Deaconess Medical Center, assignee, Identification and use of small molecules to modulate transcription factor function and to treat transcription factor associated diseases. US patent 2007/023429. 2007, June 11.
Oettgen JP, Rigby A, Libermann TA, inventors; Beth Israel Deaconess Medical Center, assignee, Identification and use of small molecules to modulate PDEF transcription factor function and to treat PDEF transcription factor associated diseases. US patent 2007/023430. 2007, June 11.